{"id":9981,"date":"2021-05-24T11:47:32","date_gmt":"2021-05-24T18:47:32","guid":{"rendered":"https:\/\/depts.washington.edu\/pandemicalliance\/?p=9981"},"modified":"2021-05-25T11:48:15","modified_gmt":"2021-05-25T18:48:15","slug":"single-dose-of-bnt162b2-mrna-vaccine-against-sars-cov-2-induces-high-frequency-of-neutralising-antibody-and-polyfunctional-t-cell-responses-in-patients-with-myeloproliferative-neoplasms","status":"publish","type":"post","link":"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/24\/single-dose-of-bnt162b2-mrna-vaccine-against-sars-cov-2-induces-high-frequency-of-neutralising-antibody-and-polyfunctional-t-cell-responses-in-patients-with-myeloproliferative-neoplasms\/","title":{"rendered":"Single Dose of BNT162b2 MRNA Vaccine against SARS-CoV-2 Induces High Frequency of Neutralising Antibody and Polyfunctional T-Cell Responses in Patients with Myeloproliferative Neoplasms"},"content":{"rendered":"<ul>\n<li style=\"font-weight: 400\"><span style=\"font-weight: 400\">Among 21 patients with myeloproliferative neoplasms (MPN), conditions in which the body overproduces blood cells, one dose of the Pfizer-BioNTech vaccine resulted in a <\/span><span style=\"font-weight: 400\">positive anti-S IgG ELISA among 76% (<\/span><span style=\"font-weight: 400\">n = <\/span><span style=\"font-weight: 400\">16) of patients, neutralizing antibodies in 8<\/span><span style=\"font-weight: 400\">6<\/span><span style=\"font-weight: 400\">% (<\/span><span style=\"font-weight: 400\">n = <\/span><span style=\"font-weight: 400\">18)<\/span><span style=\"font-weight: 400\"> of <\/span><span style=\"font-weight: 400\">patients, and a memory T cell response in 80% of patients following vaccination, indicating response rates similar to those observed among the general population. The authors highlight the need for other studies to assess responses after a second dose, as well as after immunization with the other available SARS-CoV-2 vaccines.<\/span><\/li>\n<\/ul>\n<p><i><span style=\"font-weight: 400\">Harrington et al.\u00a0(May 22, 2021). Single Dose of BNT162b2 MRNA Vaccine against SARS-CoV-2 Induces High Frequency of Neutralising Antibody and Polyfunctional T-Cell Responses in Patients with Myeloproliferative Neoplasms. Leukemia. <\/span><\/i><a href=\"https:\/\/doi.org\/10.1038\/s41375-021-01300-7\"><span style=\"font-weight: 400\">https:\/\/doi.org\/10.1038\/s41375-021-01300-7<\/span><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Among 21 patients with myeloproliferative neoplasms (MPN), conditions in which the body overproduces blood cells, one dose of the Pfizer-BioNTech vaccine resulted in a positive anti-S IgG ELISA among 76% (n = 16) of patients, neutralizing antibodies in 86% (n = 18) of patients, and a memory T cell response in 80% of patients following&#8230;<\/p>\n<div><a class=\"more\" href=\"https:\/\/depts.washington.edu\/pandemicalliance\/2021\/05\/24\/single-dose-of-bnt162b2-mrna-vaccine-against-sars-cov-2-induces-high-frequency-of-neutralising-antibody-and-polyfunctional-t-cell-responses-in-patients-with-myeloproliferative-neoplasms\/\">Read more<\/a><\/div>\n","protected":false},"author":8,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[6],"tags":[32],"topic":[31],"class_list":["post-9981","post","type-post","status-publish","format-standard","hentry","category-article-summary","tag-immunity","topic-vaccines-and-immunity"],"_links":{"self":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/comments?post=9981"}],"version-history":[{"count":1,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9981\/revisions"}],"predecessor-version":[{"id":9982,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/posts\/9981\/revisions\/9982"}],"wp:attachment":[{"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/media?parent=9981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/categories?post=9981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/tags?post=9981"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/depts.washington.edu\/pandemicalliance\/wp-json\/wp\/v2\/topic?post=9981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}